life sciences

Accumulus launches Veeva RIM integration enabling real-time regulatory submissions. Amgen early adopter reports significant time savings and operational improvements.

Accumulus Technologies unveiled Direct Connect for Veeva RIM, enabling real-time integration between regulatory systems and health authorities, reducing manual work for life sciences companies.

GXO Logistics stock fell 18% after Amazon's supply chain announcement, but strong Q1 earnings and CEO confidence suggest the decline may be overdone.

Danaher Corporation approved a $0.40 per share quarterly dividend payable July 31, 2026, demonstrating ongoing shareholder return commitment.

Cryoport reports Q1 2026 revenue of $47.8M, up 16% YoY, raising full-year guidance to $192-196M as CGT revenue surges.

Nvidia and Veeva Systems emerge as two compelling growth stocks for long-term investors, leveraging AI infrastructure and specialized cloud dominance respectively.

Danaher trades 31% below historical valuation after 36% decline, but Masimo acquisition and resumed growth suggest recovery is underway for the storied life sciences leader.

Thermo Fisher beats Q1 earnings, raises FY26 guidance on strong bioproduction demand, but warns of modest inflation risks from Middle East tensions.

JATT II Acquisition Corp closed a $60M IPO on NASDAQ under ticker $JATT, priced at $10/share, focusing on healthcare and biotech combinations via data-driven discovery approaches.

Azenta stock dropped 13.65% after-hours following an SEC Form 3 filing by a senior executive disclosing no beneficial ownership in the company.

Life sciences validation market projected to grow from $2.7B (2024) to $3.9B (2030) at 6.7% CAGR, driven by regulatory demands and digital transformation.

Crane NXT ($CXT) finalized its acquisition of Antares Vision, creating a new Detection & Traceability segment to target life sciences and food & beverage markets.

$VEEV tumbles 37% but fortress market position, AI investments, and $20B TAM suggest attractive risk-reward at 20x forward earnings.

Dassault Systèmes proposes €0.27 per share dividend for 2025, emphasizing AI-native industrial platform strategy and sustainable profitable growth.

Veeva Systems delivered 13.6% CAGR returns since 2013 IPO. Strong competitive advantages and $20B addressable market could support multimillion-dollar returns, but growth is slowing amid increasing competition.

Novo Holdings achieved 9.2% portfolio return in 2025 but total AUM fell 35% to DKK 694B, primarily due to Novo Nordisk valuation decline.

Hercules Capital insiders bought $1.9M in stock in February amid record $3.9B investment commitments and a fortress 120% dividend coverage ratio, signaling management confidence despite 52-week lows.

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.